Ahmed Nader
Simulation Technologies (United States)(US)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Hepatitis C virus research, Hepatitis B Virus Studies, Computational Drug Discovery Methods
Most-Cited Works
- → Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial(2023)21 cited
- → Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19(2023)10 cited
- → Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers(2023)5 cited
- → Hepatitis B In Silico Trials Capture Functional Cure, Indicate Mechanistic Pathways, and Suggest Prognostic Biomarker Signatures(2025)4 cited
- → Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies(2024)4 cited
- → Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs(2025)3 cited
- → A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured)(2024)2 cited
- → Correction to: Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies(2024)2 cited
- → Intramuscular Versus Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Non-inferiority Clinical Trial(2023)1 cited
- → Population pharmacokinetics and exposure-response analysis of sotrovimab in the early treatment of COVID-19(2022)1 cited